Anavex Life Sciences Corp.’s (AVXL) Buy Rating Reiterated at Maxim Group
Anavex Life Sciences Corp. (NASDAQ:AVXL)‘s stock had its “buy” rating reaffirmed by investment analysts at Maxim Group in a research note issued to investors on Monday. They presently have a $15.00 target price on the stock. Maxim Group’s price objective suggests a potential upside of 361.54% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. FBR & Co set a $10.00 price target on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Thursday, September 29th. Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.25 on Monday. The firm’s market capitalization is $116.06 million. Anavex Life Sciences Corp. has a 52 week low of $2.43 and a 52 week high of $14.84. The company has a 50-day moving average of $3.13 and a 200 day moving average of $4.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/anavex-life-sciences-corp-s-avxl-buy-rating-reiterated-at-maxim-group.html
Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. Equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.
Several large investors have recently bought and sold shares of AVXL. American International Group Inc. acquired a new stake in Anavex Life Sciences Corp. during the second quarter valued at approximately $115,000. Nationwide Fund Advisors acquired a new stake in Anavex Life Sciences Corp. during the second quarter valued at approximately $130,000. Squarepoint Ops LLC acquired a new stake in Anavex Life Sciences Corp. during the first quarter valued at approximately $107,000. Rhumbline Advisers acquired a new stake in Anavex Life Sciences Corp. during the second quarter valued at approximately $192,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Anavex Life Sciences Corp. during the second quarter valued at approximately $313,000. 10.72% of the stock is owned by institutional investors.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.